Want to see XRAY full AI Analyst Report?
XRAY Stock Chart & Stats
$10.97
$0.21(1.65%)
At close: 4:00 PM EDT
$10.97
$0.21(1.65%)
Day’s Range― - ―
52-Week Range$8.32 - $14.76
Previous CloseN/A
Volume3.96M
Average Volume (3M)4.72M
Market Cap
$1.71B
Enterprise Value$4.20B
Total Cash (Recent Filing)$239.00M
Total Debt (Recent Filing)$2.31B
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Oct 29, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend Yield7.47%
Share Statistics
EPS (TTM)-2.74
Shares Outstanding199,353,880
10 Day Avg. Volume4,794,306
30 Day Avg. Volume4,718,787
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.70
Price to Sales (P/S)0.62
P/FCF Ratio21.91
Enterprise Value/Market Cap2.46
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda45.16
Forecast
1Y Price Target
$13.00Price Target Upside18.51% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)1.52
Revenue Forecast (FY)$3.57B
Bulls Say, Bears Say
Bulls Say
Cash GenerationPositive operating cash flow in every period and TTM free cash flow of about $131M show the business can generate internal funding despite reported losses. This supports investment and debt servicing, although cash generation remains below earlier peaks.
Product EconomicsTTM gross margin near 50% and narrowing losses indicate the company retains meaningful product economics despite revenue pressure. Preserved gross profitability can support a turnaround if commercial investments restore growth, providing a base for operating leverage.
Wellspect GrowthWellspect delivered 7.1% growth through new products, geographic expansion and continued adoption, demonstrating that DENTSPLY SIRONA can create growth within selected franchises. This provides a durable diversification source while broader portfolio recovery efforts continue.
Bears Say
Revenue DeclineMulti-year revenue contraction signals persistent pressure on demand, volumes and market execution rather than a single-quarter setback. Continued declines can reduce operating leverage, weaken reinvestment capacity and make the return-to-growth plan more dependent on successful execution.
Persistent LossesA deeply negative TTM net margin and recurring losses show that revenue has not yet translated into sustainable shareholder returns. Ongoing losses constrain internal capital formation, increase reliance on operational improvement and leave less protection if demand remains weak.
Leverage And CovenantsDebt materially exceeds equity, while amended credit agreements and adjusted leverage covenants indicate heightened lender scrutiny. This can reduce financial flexibility, increase financing costs and constrain capital allocation while earnings and cash generation remain under pressure.
DENTSPLY SIRONA News
XRAY FAQ
What was DENTSPLY SIRONA Inc’s price range in the past 12 months?
DENTSPLY SIRONA Inc lowest stock price was $8.32 and its highest was $14.76 in the past 12 months.
What is DENTSPLY SIRONA Inc’s market cap?
DENTSPLY SIRONA Inc’s market cap is $1.71B.
When is DENTSPLY SIRONA Inc’s upcoming earnings report date?
DENTSPLY SIRONA Inc’s upcoming earnings report date is Oct 29, 2026 which is in 11 days.
How were DENTSPLY SIRONA Inc’s earnings last quarter?
DENTSPLY SIRONA Inc released its earnings results on Aug 06, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.348 by $0.172.
Is DENTSPLY SIRONA Inc overvalued?
According to Wall Street analysts DENTSPLY SIRONA Inc’s price is currently Undervalued.
Does DENTSPLY SIRONA Inc pay dividends?
DENTSPLY SIRONA Inc pays a Quarterly dividend of $0.16 which represents an annual dividend yield of 7.47%. See more information on DENTSPLY SIRONA Inc dividends here
What is DENTSPLY SIRONA Inc’s EPS estimate?
DENTSPLY SIRONA Inc’s EPS estimate is 0.31.
How many shares outstanding does DENTSPLY SIRONA Inc have?
DENTSPLY SIRONA Inc has 199,353,880 shares outstanding.
What happened to DENTSPLY SIRONA Inc’s price movement after its last earnings report?
DENTSPLY SIRONA Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.348. Following the earnings report the stock price went down -7.973%.
Which hedge fund is a major shareholder of DENTSPLY SIRONA Inc?
Currently, no hedge funds are holding shares in XRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DENTSPLY SIRONA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.00 (18.51% Upside)
$13.00 (18.51% Upside)
Blogger Sentiment
Neutral
XRAY Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 10.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.10%
12-Months-Change
Fundamentals
Return on Equity
-39.81%
Trailing 12-Months
Asset Growth
-14.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
DENTSPLY SIRONA Inc
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
XRAY Company Deck
XRAY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.View all XRAY earnings summariesXRAY Net sales Breakdown
15.71% Equipment & Instruments
12.45% CAD/CAM
39.92% Essential Dental Solutions
6.17% Orthodontics
16.93% Implants & Prosthetics
8.83% Wellspect Healthcare
XRAY Stock 12 Month Forecast
Average Price Target
$13.00
▲(18.51% Upside)
Technical Analysis
Ownership Overview
0.66% Insiders
32.71% Mutual Funds
1.39% Other Institutional Investors
39.46% Public Companies and
Individual Investors